A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2023.2288683 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Rongqi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Piperidines, Adenine, Cost-Benefit Analysis, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Research Support Project for Pharmacoeconomics and Health Technology Evaluation of Zhejiang Provincial Pharmaceutical Association, Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department.
Abstract (Originalsprache)
OBJECTIVE: This article examined the cost-effectiveness of zanubrutinib and ibrutinib for managing relapsed and refractory chronic lymphocytic leukemia from the viewpoint of payers in China and the US. METHODS: Markov models were employed to conduct comparisons. Baseline characteristics and clinical data were extracted from the ALPINE study. The cost-effectiveness outcome indicators encompassed cost, quality-adjusted life years, and the incremental cost-effectiveness ratio. RESULTS: The Markov model analysis revealed that the zanubrutinib group incurred an incremental cost per patient of $-24,586.53 compared to the ibrutinib group. The zanubrutinib group exhibited an incremental utility per capita of 0.28 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio of $-88,068.16 per quality-adjusted life year, which is lower than the payment threshold in China. The willingness-to-pay value in China for 2022 was three times the country's gross domestic product per capita. In the US, patients in the zanubrutinib group experienced per capita incremental costs of $-79,421.56, per capita incremental utility of 0.28 quality-adjusted life years, and an incremental cost-effectiveness ratio of $-284,485.45 per quality-adjusted life year. CONCLUSION: For Chinese payers, zanubrutinib exhibited superior cost-effectiveness compared to ibrutinib. Zanubrutinib proved to be a more affordable option for US payers when considering the payment threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Pharmacy, Zhejiang University of Traditional Chinese Medicine Affiliated Wenzhou Hospital, Wenzhou, Zhejiang, China.
- Clinical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Förderung
- Research Support Project for Pharmacoeconomics and Health Technology Evaluation of Zhejiang Provincial Pharmaceutical Association
- Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
- A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department
Zitieren
APA
Li, R., Wang, C., Ye, Z., Chen, Y., Xu, J., Chen, C., Yang, J., Fu, J., Zhou, T., Zhou, Z., & Zhang, X. (2024). A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2288683
Vancouver
Li R, Wang C, Ye Z, Chen Y, Xu J, Chen C, et al. A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2288683
BibTeX
@article{Li2024,
author = {Li, Rongqi and Wang, Chenxiang and Ye, Zhongjiang and Chen, Yizhang and Xu, Jingyao and Chen, Chuang and Yang, Jianhui and Fu, Jing and Zhou, Tao and Zhou, Ziye and Zhang, Xiuhua},
title = {A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2023.2288683}
}
EUVIMED